ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|September 14, 2021
Repligen and Navigo GmbH Launch Industry-First Protein A Ligand for Purification of pH-Sensitive Antibodies
Author(s)BioPharm International Editors
Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.
Advertisement
Repligen Corporation, a life sciences company focused on bioprocessing technology, and Navigo Proteins GmbH, a protein engineering company, announced on Sept. 9, 2021, the completion of the development and validation of a novel protein A ligand, the NGL-Impact A Hi pH, that addresses antibody aggregation in low pH elution buffers and challenges associated with Fc-fusion proteins.
Protein A affinity ligands enable the affinity purification of monoclonal antibody-based biologic drugs in Protein A chromatography media. However, according to a company press release, this is the first ligand to address antibody aggregation in low pH elution buffers. It was specifically developed to address pH-sensitive antibodies and Fc-fusion proteins, but it can also be considered for “platform” use due to its broad pH operating range and high performance across all antibodies.
“[This new ligand] addresses one of the major pain points in antibody drug purification, which is the formation of aggregates during Protein A elution,” said Ralf Kuriyel, senior vice-president of R&D at Repligen, in the company press release. “Our new NGL-Impact A Hi pH ligand has demonstrated in customer evaluations two-fold lower levels of aggregate formation while maintaining high dynamic binding capacity and excellent caustic stability. We have completed all scale-up and validation work and now look forward to this ligand being commercialized on a new resin later this year, through our partnership with Purolite.”
“The introduction of a high pH, high performing ligand into the market represents a potential real cost and time savings for developers of pH-sensitive antibodies and Fc-fusion proteins,” said Henning Afflerbach, CEO of Navigo Proteins, in the press release. “We believe the performance enabled by this ligand will prove very attractive in the market, for purification of all antibodies and Fc-containing proteins.”
Source:
Advertisement
Related to this article
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5